Taking a Break From TKIs Unlikely to Shorten Survival

A unique study in patients with renal cell carcinoma on tyrosine kinase inhibitors (TKIs) shows that taking a break from the drugs is feasible and cost-effective.

Related Keywords

United States ,Ohio ,United Kingdom ,Cleveland ,Jenny Hewison ,Moshe Ornstein ,Janine Bestall ,Janet Brown ,Leeds University School Of Medicine ,United Kingdom National Institute For Health ,Uk National Institute For Health ,University Of Leeds ,Care Research ,University Of Sheffield ,National Institute ,Medscape Medical ,Leeds University School ,Treatment Strategies ,Cleveland Clinic ,Malignant Kidney Neoplasm ,Kidney Cancer ,Renal Cell Cancer ,Renal Cell Carcinoma ,Ancer Kidney ,Ancer Renal Cell ,Biologic Therapy ,Tyrosine Kinase Inhibitor ,Rlotinib ,Efitinib ,Matinib ,U11248 ,Unitinib ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Ituximab ,Rastuzumab ,Cancer ,Alignant Neoplasia ,Arcinoma ,The ,